Primary central nervous system lymphoma
Conditions
Interventions
Experimental group:Patients planning to undergo autologous hematopoietic stem cell transplantation will be treated with a transplantation pretreatment regimen of certipie + simustine + cytarabine
Sponsors
Henan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 to 70 years old; 2. Patients with primary central nervous system lymphoma who have been diagnosed and have achieved PR or above after induction therapy can receive ASCT. 3. ECOG score: 0-2 points; 4. Expected survival period: >=3 months; 5. The functions of major organs are normal, and the laboratory test results meet the following standards: a. Alanine aminotransferase (ALT) =2106/kg; 7. Voluntarily participate in this clinical trial, understand the research procedures and be able to sign the informed consent form in person.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2. Those with a history of bone marrow transplantation and/or hematopoietic stem cell transplantation; 3. There are other hematological diseases that affect bone marrow hematopoietic function; 4. Those who are allergic to the research drugs and their related metabolites; 5. Uncontrolled active infections; 6. Has a history of severe heart and lung diseases that cannot be controlled; 7. As determined by the researcher, there are serious concomitant diseases that endanger the patient's safety or affect the patient's completion of the study; 8. Other circumstances that the researcher deems unsuitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 years progression-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2 years overall survival rate;Safety;Overall survival;Event-free survival;Overall remission rate;Complete remission rate; | — |
Countries
China
Contacts
Public ContactXiaoli Yuan
Henan Provincial People's Hospital
Outcome results
None listed